Ensign Peak Advisors
CRBU icon

Ensign Peak Advisors’s Caribou Biosciences CRBU Stock Holding History

Ensign Peak Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-76,657
Closed -$481K – 1775
2022
Q4 		$481K Sell
76,657
-11,830
-13% -$105K ﹤0.01% 1628
2022
Q3 		$934K Buy
88,487
+17,879
+25% +$167K ﹤0.01% 1107
2022
Q2 		$384K Hold
70,608
– – ﹤0.01% 1570
2022
Q1 		$648K Buy
70,608
+5,820
+9% +$61.3K ﹤0.01% 1438
2021
Q4 		$978K Buy
+64,788
New +$1.26M ﹤0.01% 1300

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors's CRBU Position: Q1 2023 in Review

Ensign Peak Advisors sold out of Caribou Biosciences (CRBU) in Q1 2023, closing a stake of 76,657 shares — an estimated $481K sold.

Ensign Peak Advisors first reported a position in CRBU in Q4 2021 and held it in 5 quarters. The position peaked at $978K in Q4 2021. 126 funds tracked by Wall St. Rank hold CRBU as of Q1 2023.

  • Ensign Peak Advisors reported no remaining Caribou Biosciences position as of Q1 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 76,657 Caribou Biosciences shares in Q1 2023, an estimated $481K.
  • Ensign Peak Advisors first reported a position in Caribou Biosciences in Q4 2021 and held it in 5 quarters.
  • Ensign Peak Advisors's Caribou Biosciences position peaked at $978K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2023.

Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.